$XBI $85.10 | -4.04%
Covid Updates
$NVAX -7.4% Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States. source
Pipeline Updates
$VBIV -7.9% VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults source
$ORPH +1.5% Orphazyme announces update on regulatory review of arimoclomol in the European Union source
$PCVX -1.3% Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults source
$RLMD +6.7% Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential. source
$HZNP -1.4% Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED). source
$CYCN -3.4% Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration. source
$LNTH -0.3% Lantheus Receives U.S. FDA Approval of New Manufacturing Facility. source
$AYLA -5.0% Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors. source
$KMPH -3.2% KemPharm Completes KP1077 Pre-IND Meeting Process with FDA. source
$CYTK -7.0% Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. source
$KOD -80.4% Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration. source
Business Updates
$OCGN -26.0% Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock. source
$MRNA -6.4% Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America. source
Posted by FS/JM
Comments